Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03173534 · ClinicalTrials.gov registry record · NA
WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
A NA study, sponsored by samir kapadia.
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
NCT03173534: Completed NA study, sponsored by samir kapadia.
NCT03173534 is a NA study that has completed, run by samir kapadia. The registered enrollment target is 350 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03173534, a NA study, has completed, sponsored by samir kapadia.
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of the left atrial appendage occlusion with WATCHMAN Device in prevention of stroke and bleeding in patients with atrial fibrillation (AF) undergoing transcatheter aortic valve replacement (TAVR).
Interventions
- DEVICE TAVR
- DEVICE WATCHMAN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2017-12-15 |
| Est. Completion | 2022-12-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03173534
The ClinicalTrials.gov registry entry for NCT03173534 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is samir kapadia, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAVR is the first listed.
NCT03173534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03173534 about?
NCT03173534 is a clinical study titled "WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement". To evaluate the safety and effectiveness of the left atrial appendage occlusion with WATCHMAN Device in prevention of stroke and bleeding in patients with atrial fibrillation (AF) undergoing transcatheter aortic valve replacement (TAVR).
What is the current status of trial NCT03173534?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2017-12-15. Estimated completion is 2022-12-06.
What interventions are being tested in trial NCT03173534?
The interventions under investigation include: TAVR (DEVICE), WATCHMAN (DEVICE).
Who is sponsoring clinical trial NCT03173534?
This trial is sponsored by samir kapadia, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.